【摘要】 目的：探讨洛匹那韦/利托那韦（克力芝）治疗新型冠状病毒肺炎（COVID-19）的临床疗效及安全性。方法：回顾性分析2020年1月23日～3月11日南充市中心医院治愈出院的22例COVID-19患者的临床资料，抗病毒治疗方案均含洛匹那韦/利托那韦。收集患者的基本特征、临床症状、实验室指标、肺部影像学及不良反应发生情况、住院时间等资料。结果：全部患者均口服洛匹那韦/利托那韦抗病毒治疗，均治疗出院，住院时间11～42(21.09±8.513)d，临床症状缓解时间约5～7 d，核酸转阴时间4～38(13.32±8.916)d，肺部影像学吸收时间0～29(12.27±5.742)d。出现不良反应10例，发生率为45.5%，主要表现为恶心、腹泻、转氨酶升高、血脂升高等。结论：洛匹那韦/利托那韦联合其他抗病毒药物治疗尚未观察到显著临床疗效，早期使用可能潜在缩短病程、避免疾病进展的作用，但药物不良反应发生率较高，尤其是胃肠道反应、肝毒性及血脂代谢异常。临床应用时尤其应关注其安全性，是否具有临床使用价值、如何选择用药时机尚需大样本数据研究。更多还原

【Abstract】 Objective:To explore the clinical efficacy and safety of lopinavir/ritonavir in the treatment of coronavirus disease(COVID-19). Methods:A total of 22 patients with Covid-19 who were discharged from Nanchong Central Hospital from January 23,2020 to March 11,2020 were retrospectively analyzed. All the antiviral treatment regiments included lopinavir/ritonavir.The basic characteristics,clinical symptoms,laboratory indicators,pulmonary imaging,the adverse reactions and the hospital stays of the patients were collected for analysis. Results:All patients received oral lopinavir/ritonavir antiviral therapy,and were discharged from hospital. The hospital stay was 11～42(21.09±8.513)d. The clinical symptom relief time was 5～7 d,and the nucleic acid negative conversion time was 4～38(13.32±8.916)d. The absorption time of lung imaging was 0～29(12.27±5.742)d.Adverse reactions occurred in 10cases(45.5%),and the main manifestations were nausea,diarrhea,elevated transaminase,elevated blood lipid,etc.Conclusions:Lopinavir/ritonavir combined with other antiviral drugs therapy has not been observed significant clinical efficacy,early use may shorten the duration of symptoms,to avoid the disease progression,but with a greater incidence of adverse drug reactions,especially in the gastrointestinal tract reaction,liver toxicity and blood lipid metabolic abnormalities. In clinical application,we should focus on its safety. Whether it has clinical use value and how to choose the timing of drug use still need to be studied with large sample data.更多还原